

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	"6165415"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:04
S2	2	("6165415").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/02/01 14:05
S3	2	("6984628").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/02/01 14:19
S4	2	("5597559").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/02/01 14:20
S5	2	("4645768").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/02/01 14:36
S6	38388	prostaglandin\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:36
S7	38449	prostagan\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:45

EAST Search History

S8	1412	trefoil	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:45
S9	245021	peptide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:45
S10	523	S8 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:48
S11	3804	tff	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:48
S12	3804	TFF	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:02
S13	4278	S10 or S12	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:48
S14	2686486	arachidonic acid	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:49

EAST Search History

S15	2708367	GLA or (gammalinolenic acid) or (eicosapentaenoic acid)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:49
S16	640	latanoprost or xalatan	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:54
S17	252	bimatoprost or lumigan	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:56
S18	191	travoprost or (Travatan)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:57
S19	676	S16 or S17 or S18	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:57
S20	38635	S7 or S19	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 14:57
S21	134	S7 and S13	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:06

EAST Search History

S22	3	S13 and S19	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:00
S23	5466	S7 near S20 S13	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:11
S24	40	prostagland\$ and TFF	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:12
S25	531805	eye or ophalm\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:20
S26	8433	S25 and S7	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:21
S27	4951	S19 or S13	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:21
S28	426	S26 and S27	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:23

EAST Search History

S29	3920	S12 or (peptide near15 trefoil)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:24
S30	24	S28 and S29	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:35
S31	95	prostamide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:36
S32	2	S31 and S13	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:36
S33	38710	prostag\$ or prostam\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:55
S34	152	hTTF	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:55
S35	2757	TTf	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:55

EAST Search History

S36	1412	trefoil	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:55
S37	245197	peptide\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:56
S38	1725305	factor\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:56
S39	1827965	S37 or S38	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:56
S40	1412	S36 near5l7	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:56
S41	333	S36 near5 S39	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:57
S42	103	S40 and S33	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:57

EAST Search History

S43	101	(dose\$ or composition\$ or tablet\$ or capsule\$)and S42	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 15:59
S44	72	xalatan	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 17:59
S45	0	xalatan and tff	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 17:44
S46	3401	"dry eye"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/01 17:59
S47	7	S44 and S46	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:18
S48	38449	prostaglan\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:19
S49	640	latanoprost or xalatan	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:19

EAST Search History

S50	252	bimatoprost or lumigan	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:19
S51	191	travoprost or (Travatan)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:19
S52	676	S49 or S50 or S51	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:19
S53	38635	S48 or S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:19
S54	310	S53 and blepharitis	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/02 09:32
S55	2	("6,833,358").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/02/02 09:32
S56	275	bimatoprost or lumigan	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/12 09:03

EAST Search History

S57	3	S56 and (trefoil or "trefoil factor" or tff)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 09:10
S58	6263	pS2	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 09:11
S59	12815	"pS2" or "spasmolytic polypeptide" or "intestinal trefoil factor" or "ITF"	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 09:12
S60	70	S59 and glaucoma	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 09:12
S61	320	S59 and (prostag\$ or bimatoprost or lumigan or prostam\$)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 10:39
S62	36	S60 and S61	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 09:24
S63	1	("5688819").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/04/12 10:43
S64	1	("6525018").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/04/12 11:18
S65	32191	tff\$	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 11:18
S66	10487	\$tff	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 11:19

EAST Search History

S67	38815	S65 or S66	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 11:19
S68	136	S67 and (prostag\$ or prostam\$)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 11:20
S69	78	S68 and (eye or ocula\$ or opthal\$)	US-PGPUB; USPAT; USOCR; EPO; DERWENT	OR	ON	2007/04/12 11:20

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DLA PIPER RUDNICK GRAY CARY US, LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US
NUMBER OF CLAIMS: 289
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 11309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 18 USPATFULL on STN
AB Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence of hyperemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2006:54653 USPATFULL <<LOGINID::20070411>>
TITLE: Compositions and methods comprising prostaglandin related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
INVENTOR(S): Bakhit, Peter G, Huntington Beach, CA, UNITED STATES
Graham, Richard, Irvine, CA, UNITED STATES
Olejnik, Orest, Coto de Caza, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006046958	A1	20060302
APPLICATION INFO.:	US 2003-521367	A1	20040825 (10)
	WO 2004-US27777		20040825
			20050112 PCT 371 date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Allergan Inc, 2525 Dupont Drive, Irvine, CA, 92612, US		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	761		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 18 USPATFULL on STN
AB The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:298522 USPATFULL <<LOGINID::20070411>>
TITLE: Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
INVENTOR(S): Bookbinder, Louis H., San Diego, CA, UNITED STATES
Kundu, Anirban, San Diego, CA, UNITED STATES
Frost, Gregory I., Del Mar, CA, UNITED STATES
Haller, Michael F., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S) : Keller, Gilbert A., Belmont, CA, UNITED STATES
Dylan, Tyler M., San Diego, CA, UNITED STATES
Halozyme, Inc., San Diego, CA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005260186	A1	20051124
APPLICATION INFO.:	US 2005-65716	A1	20050223 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-795095, filed on 5 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-452360P	20030305 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DLA PIPER RUDNICK GRAY CARY US, LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US	
NUMBER OF CLAIMS:	255	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	10953	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 13 OF 18 USPATFULL on STN
AB Compounds of Formula I: ##STR1## wherein X.sup.1, X.sup.2, L.sup.1,
A, R, L.sup.2, R.sup.1, R.sup.12, R.sup.12a, R.sup.13, R.sup.14 and
R.sup.14a are as defined herein, are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:227486 USPATFULL <<LOGINID::20070411>>
TITLE: Substituted pyrazole urea compounds for the
treatment of inflammation
INVENTOR(S) : Huang, He, Durham, NC, UNITED STATES
Stealey, Michael A., Libertyville, IL, UNITED STATES
Hanson, Gunnar J., Durham, NC, UNITED STATES
Lennon, Patrick J., Webster Groves, MO, UNITED STATES
Hamper, Bruce C., Kirkwood, MO, UNITED STATES
Xie, Jin, Ballwin, MO, UNITED STATES
Oburn, David S., Ferguson, MO, UNITED STATES
Wolfson, Serge G., Chesterfield, MO, UNITED STATES
Fletcher, Theresa R., Kirkwood, MO, UNITED STATES
Heier, Richard F., Columbia, IL, UNITED STATES
Reding, Matthew T., University City, MO, UNITED STATES
Clare, Michael T., Skokie, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005197338	A1	20050908
APPLICATION INFO.:	US 2004-970769	A1	20041021 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-512868P	20031021 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	13609	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 14 OF 18 USPATFULL on STN

AB The present invention provides compositions and methods for lowering intraocular pressure in a subject. More particularly, the invention provides a combination therapy for the treatment of an ophthalmic disorder mediated by an elevated intraocular pressure comprising administering to a subject an aquaporin modulating agent in combination with an aqueous humor modulating agent, where the aqueous humor modulating agent lowers intraocular pressure by a pathway other than the modulation of aquaporin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:273290 USPATFULL <<LOGINID::20070411>>

TITLE: Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure

INVENTOR(S): Wax, Martin B., Westlake, TX, UNITED STATES

PATENT ASSIGNEE(S): Pharmacia Corporation (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2004213782 A1 20041028

APPLICATION INFO.: US 2004-768266 A1 20040130 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2003-444509P 20030203 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102

NUMBER OF CLAIMS: 55

EXEMPLARY CLAIM: 1

LINE COUNT: 2233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 18 USPATFULL on STN

AB Disclosed is the surprising discovery that prostanoids function to effectively increase the transport of therapeutic agents into the eye. The invention thus provides new methods, combinations, formulations, compositions and kits for prophylactic and therapeutic intervention in various ocular diseases, disorders and infections and in combined use with surgical intervention.

ACCESSION NUMBER: 2004:255299 USPATFULL <<LOGINID::20070411>>

TITLE: Prostanoids augment ocular drug penetration

INVENTOR(S): Sponsel, William Eric, San Antonio, TX, UNITED STATES

Glickman, Randolph D., San Antonio, CA, UNITED STATES

Paris, Gianmarco, San Antonio, TX, UNITED STATES

Bernal, Vanessa, San Antonio, TX, UNITED STATES

Graybill, John, San Antonio, TX, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004198829 A1 20041007

APPLICATION INFO.: US 2004-476090 A1 20040604 (10)

WO 2002-US13057 20020423

NUMBER DATE

PRIORITY INFORMATION: US 2001-285856P 20010423 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Shelly P M Fussey Williams, Morgan & Amerson, Suite 1100, 10333 Richmond, Houston, TX, 77042

ANSWER 21 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:656805 CAPLUS <>LOGINID::20070412>>
 DOCUMENT NUMBER: 139:192011
 TITLE: Management of mucosal viscosity by TFF
 monomer peptides
 INVENTOR(S): Thim, Lars; Poulsen, Steen Seier
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068817	A1	20030821	WO 2003-DK83	20030210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003205555	A1	20030904	AU 2003-205555	20030210
EP 1476466	A1	20041117	EP 2003-702373	20030210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005524641	T	20050818	JP 2003-567943	20030210
US 2003215431	A1	20031120	US 2003-364751	20030211
PRIORITY APPLN. INFO.:			DK 2002-200	A 20020211
			US 2002-361374P	P 20020226
			WO 2003-DK83	W 20030210
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L19 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:150521 CAPLUS <>LOGINID::20070412>>
 DOCUMENT NUMBER: 138:180763
 TITLE: Treating eye disorders using intestinal
 trefoil proteins
 INVENTOR(S): Podolsky, Daniel K.
 PATENT ASSIGNEE(S): The General Hospital Corp., USA
 SOURCE: U.S., 31 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 16
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6525018	B1	20030225	US 1999-313434	19990517
US 2003134797	A1	20030717	US 2002-313642	20021206
US 2003186886	A1	20031002	US 2003-449456	20030530
PRIORITY APPLN. INFO.:			US 1996-631469	A1 19960412
			WO 1997-US6004	W 19970411
			US 1999-313434	A1 19990517
			US 2002-313642	A1 20021206
			US 2003-362310	A2 20030219
REFERENCE COUNT:	19	THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS		

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:977676 CAPLUS <>LOGINID::20070412>>
 DOCUMENT NUMBER: 138:50261
 TITLE: Mucosal repair by TFF dimer peptides
 INVENTOR(S): Thim, Lars; Poulsen, Steen Seier
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102403	A1	20021227	WO 2002-DK396	20020613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003153496	A1	20030814	US 2002-172647	20020613
EP 1401481	A1	20040331	EP 2002-737871	20020613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534075	T	20041111	JP 2003-504989	20020613
US 2006211605	A1	20060921	US 2006-439690	20060523
PRIORITY APPLN. INFO.:			DK 2001-926	A 20010614
			US 2001-303181P	P 20010705
			US 2002-172647	B1 20020613
			WO 2002-DK396	W 20020613

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:395131 CAPLUS <>LOGINID::20070412>>
 DOCUMENT NUMBER: 142:435805
 TITLE: Ophthalmic composition comprising
 prostaglandin-related compounds and
 trefoil factor family peptides for
 treatment of glaucoma with reduced hyperemia
 INVENTOR(S): Bakhit, Peter G.; Graham, Richard; Olejnik, Orest
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039619	A1	20050506	WO 2004-US27777	20040825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283091	A1	20050506	AU 2004-283091	20040825
CA 2541123	A1	20050506	CA 2004-2541123	20040825
EP 1667705	A1	20060614	EP 2004-782288	20040825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004014868	A	20061128	BR 2004-14868	20040825
JP 2007507498	T	20070329	JP 2006-533858	20040825
US 2006046958	A1	20060302	US 2005-521367	20050112
PRIORITY APPLN. INFO.:			US 2003-508445P	P 20031003
			WO 2004-US27777	W 20040825

TI Ophthalmic composition comprising prostaglandin-related
 compounds and trefoil factor family peptides for
 treatment of glaucoma with reduced hyperemia
 AB Compns., methods, and pharmaceutical products related to
 prostaglandin-related compds. and trefoil factor
 family peptides for the treatment of glaucoma with a reduced
 occurrence of hyperemia are disclosed herein. For example, a composition
 contained bimatoprost 0.03, tamarind seed polysaccharide 0.05, . . . 7.0
 was prepared A drop of this composition was added at least once a day to
 several
 patients suffering from glaucoma. Reduction in intraocular pressure
 was observed for all patients with reduced hyperemia.
 ST prostaglandin trefoil factor peptide
 ophthalmic glaucoma hyperemia
 IT Trefoil factor proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (TFF1 (trefoil factor 1); ophthalmic composition
 comprising prostaglandin-related compds. and trefoil
 factor family peptides for treatment of glaucoma with
 reduced hyperemia)
 IT Trefoil factor proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(TFF3 (trefoil factor 3); ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

IT Antiglaucoma agents
Glaucoma (disease)
Human
Hyperemia
(ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

IT Drug delivery systems
(ophthalmic; ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

IT Drug delivery systems
(solns., ophthalmic; ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

IT Polysaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tamarind seed, mucoadhesive; ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

IT 9004-32-4, Sodium carboxymethylcellulose 9004-65-3,
Hydroxypropylmethylcellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mucoadhesive; ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

IT 120373-24-2, Unoprostone isopropyl ester 130209-82-4, Latanoprost
155206-00-1, Bimatoprost 157283-68-6, Travoprost
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic composition comprising prostaglandin-related compds. and trefoil factor family peptides for treatment of glaucoma with reduced hyperemia)

AB Compns., methods, and pharmaceutical products related to prostaglandin-related compds. and trefoil factor family peptides for the treatment of glaucoma with a reduced occurrence of hyperemia are disclosed herein. For example, a composition contained bimatoprost 0.03, tamarind seed polysaccharide 0.05, TFF1 0.15, boric acid 0.06, sodium borate decahydrate 0.035, sodium chloride 0.53, benzalkonium chloride 0.005, water to 100%, resp., and HCl or NaOH to pH 7.0 was prepared. A drop of this composition was added at least once a day to several patients suffering from glaucoma. Reduction in intraocular pressure was observed for all patients with reduced hyperemia.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:72748 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 136:146104
TITLE: Human stress genes identified using DNA microarrays
INVENTOR(S): Chenchik, Alex; Lukashev, Matvey E.
PATENT ASSIGNEE(S): Clontech Laboratories, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S.
 Ser. No. 441,920.
 CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002009730	A1	20020124	US 2001-782909	20010213
PRIORITY APPLN. INFO.:			US 1998-222256	B2 19981228
			US 1999-440305	B2 19991117
			US 1999-441920	A2 19991117
IT 148734-79-6, Ribosomal protein L 6 (human clone pr6)			150789-84-7,	
Protein (human clone 2.2 gene XPGC reduced)			151440-11-8, Protein (human	
gene bax isoform β reduced)			152989-72-5 154007-23-5, Endoglin	
(human precursor reduced)			154575-14-1 155362-06-4 158132-59-3	
159318-48-6 161736-37-4 161736-44-3 162063-82-3 164639-53-6,				
Protein (human KG-1 cell 631-amino acid)			167362-01-8, Ribosomal protein	
S5 (human)			168256-72-2, Cadherin 6 (human clone B1-1 precursor)	
169443-30-5, Lumican (human eye clone humlum19/pBS)				
169595-23-7 171905-09-2 172253-26-8 172253-58-6 172522-18-8				
172642-85-2 173330-46-6 173834-22-5 176430-65-2 177530-33-5,				
Protein (human gene ENX-1)			177893-92-4 177894-31-4 177968-09-1	
179158-51-1 179158-61-3 179311-59-2, Protein (human gene ECA39)				
179467-08-4 179671-71-7 180033-67-4 180191-82-6 180855-36-1,				
Protein (human clone wb1c gene white)			181315-07-1 182022-35-1	
182178-67-2 182373-12-2 183627-57-8 184092-09-9 184973-78-2				
185439-22-9 186050-34-0, Protein FAP48 (human FKBP-associated)				
186102-42-1, Protein (human gene MyD88 reduced)			186777-25-3	
186916-79-0, Protein (human gene OCTS3)			187684-93-1 188043-14-3	
188204-78-6 188794-46-9, Cyclin A1 (human)			188794-62-9 188993-27-3	
189202-53-7 189326-55-4 190607-15-9 191046-12-5 191046-20-5				
191046-42-1 191175-53-8 192728-23-7 193489-07-5 195397-09-2				
196223-22-0 197665-83-1 198582-99-9, Repressor (human gene CHD1)				
198653-80-4 199543-67-4 199619-76-6, Syntaxin 7 (human brain)				
199619-80-2 200445-09-6, Protein (human clone p38-2G4 gene PA2G4)				
200446-30-6 201366-58-7 201752-84-3, Protein Daxx (human reduced)				
201949-89-5 202759-46-4 202938-20-3 203010-65-5 203268-05-7,				
Calmegin (human testis reduced)			203592-57-8 203674-18-4 204530-79-0	
204597-33-1 205070-69-5 206282-81-7 206368-70-9 206456-00-0				
206570-00-5 207242-72-6 207354-75-4 207521-86-6, Protein (human				
clone 239955 gene GAS2)			207754-38-9 207754-88-9, Caveolin 3 (human	
gene CAV3 reduced)				
208541-49-5, Protein (human gene Rad51d)				
208602-63-5, Protein (human gene SLC22A)			208670-32-0 210044-83-0	
210413-98-2 210772-90-0 210978-57-7, Liprin-β2 (human C-terminal				
fragment)			211170-90-0 211371-34-5, Protein (human gene Cyr61)	
211564-38-4, Protein BAP1 (human BAI-associated)			211750-45-7	
211930-21-1, Protein MOAT-B (human)			212707-31-8 212900-99-7, Protein	
(human clone HH-111 gene NOTCH4)			213260-32-3 214145-60-5	
215518-61-9, Protein (human gene DPM2)			215665-62-6 217307-55-6	
217947-92-7 218781-94-3 218914-15-9 219814-13-8 220073-38-1,				
Aquaporin 8 (human gene AQP8)			220137-43-9, Protein (human gene SKB1Hs)	
221340-64-3 221546-33-4 221893-91-0 221895-85-8 224433-33-4				
224954-05-6 231947-64-1 238402-73-8 244204-32-8 246228-95-5				
246242-89-7 250600-58-9 260388-00-9, Protein (human gene COQ7)				
271800-13-6 287744-61-0 306331-56-6, Protein (human A2058 melanoma				
gene MTA1)			322767-08-8 385849-12-7, Beta2-syntrophin (human gene	
SNTB2)			385849-13-8 385849-15-0 385849-24-1, Inhibitor of apoptosis	
protein 1 (human)			385849-28-5 385849-33-2 385849-40-1, Integrin	
α 6 (human FG cell)			385849-47-8, Cyclin D3 (human gene CCND3)	
385849-49-0, Dynein light chain 1 (human gene hdcl1)			385849-55-8	
385849-59-2 385849-60-5 385849-62-7, Interleukin 1 receptor (human)				

385849-66-1 385849-70-7 385849-76-3 385849-77-4 385849-78-5
 385849-80-9 385849-81-0 385849-84-3 385849-85-4 385849-86-5,
 Annexin II (human) 385849-92-3, RNA formation factor NF-IL6 β
 (human) 385856-66-6 391960-98-8, GenBank CAA78055 391960-99-9,
 Protein (human gene TP53) 391961-00-5, Protein (human gene TP53)
 391961-01-6 391961-02-7 391961-03-8 391961-04-9, Heat shock factor 1
 (human gene TCF5) 391961-05-0, HsRad51 (human gene HsRAD51)
 391961-06-1 391961-07-2, MAP kinase kinase (human) 391961-08-3
 391961-09-4 391961-10-7, Excision repair protein (human) 391961-12-9,
 Rad (human) 391961-13-0, Protein (human 732-amino acid) 391961-14-1,
 Protein (human 295-amino acid) 391961-15-2, Protein (human gene ERCC3)
 391961-16-3, Protein (human 609-amino acid) 391961-17-4, Protein (human
 327-amino acid) 391961-18-5, Protein (human 341-amino acid)
 391961-19-6 391961-20-9 391961-21-0, Protein (human 152-amino acid)
 391961-22-1 391961-23-2 391961-24-3 391961-25-4 391961-26-5, Pur
 (human gene pur-alpha) 391961-27-6, Protein (human gene TOP1)
 391961-28-7, Protein (human gene TOP2A) 391961-29-8, Protein (human gene
 MGMT) 391961-30-1 391961-31-2 391961-32-3 391961-33-4, Protein
 (human gene hmlh1) 391961-34-5, HHR23A protein (human gene HHR23A)
 391961-35-6 391961-36-7, Protein kinase (human) 391961-37-8, MAP
 kinase (human) 391961-38-9 391961-39-0, Heat-shock protein HSP 60
 (human) 391961-40-3 391961-41-4 391961-42-5, TLS-CHOP (human gene
 TLS/CHOP) 391961-43-6 391961-44-7, DNA-PK (human) 391961-45-8
 391961-46-9, BRCA2 (human gene BRCA2) 391961-47-0, Protein (human
 312-amino acid) 391961-48-1 391961-49-2, Vimentin (human clone M98C1)
 391961-50-5, Protein (human gene VIM) 391961-51-6 391961-52-7
 391961-53-8 391961-54-9 391961-55-0 391961-56-1, Heat shock protein
 (human gene HSPA1L) 391961-57-2, RAD52 (human cell line Jurkat)
 391961-58-3, Protein (human gene ATM) 391961-59-4, MAP kinase kinase 6
 (human gene MKK6) 391961-60-7, Rad50 (human gene Rad50) 391961-61-8
 391961-62-9 391961-63-0 391961-64-1 391961-65-2 391961-66-3
 391961-67-4 391961-68-5, ERK5 (human clone 3-1) 391961-70-9
 391961-71-0 391961-75-4 391961-76-5, Protein (human 380-amino acid)
 391961-77-6, MEK5 (human clone 3-2)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; human stress genes identified using DNA
 microarrays)

IT 391961-78-7 391961-79-8, Protein (human gene hMSH2) 391961-81-2
 391961-83-4 391961-84-5 391961-85-6 391961-86-7 391961-87-8,
 Protein (human 653-amino acid) 391961-88-9, Protein (human gene hPMS1)
 391961-89-0, Protein (human gene hPMS2) 391961-90-3 391961-91-4, MutY
 (human gene hMYH) 391961-92-5, Beta A4 crystallin (human gene CRYBA4)
 391961-94-7, Beta B1-crystallin (human) 391961-95-8, Crystallin beta-B2
 (human gene CRYB2B) 391961-96-9, BetaB3 crystallin (human)
 391961-97-0, GC kinase (human) 391961-98-1, Protein (human gene CYP2A)
 391961-99-2, Protein (human 494-amino acid) 391962-00-8, Protein (human
 clone 1 489-amino acid) 391962-01-9, Protein (human gene CYP2A)
 391962-02-0, Protein (human gene CYP2C) 391962-03-1, Protein (human gene
 CYP2C) 391962-04-2, Protein (human 370-amino acid) 391962-05-3,
 Cytochrome P450 (human) 391962-06-4, Cytochrome (human gene CYP2C19)
 391962-07-5, Protein (human 551-amino acid) 391962-08-6 391962-09-7
 391962-10-0, Human P5 (human) 391962-11-1, Protein (human 724-amino
 acid) 391962-12-2, Heat-shock protein HSP70B (human) 391962-13-3,
 Protein (human gene HSPA1L) 391962-14-4 391962-15-5, Heat shock
 protein (human gene HSPA2) 391962-16-6, Protein (human 493-amino acid)
 391962-17-7, Protein (human gene CYP2F1) 391962-18-8 391962-19-9,
 Protein (human gene CYP1A1) 391962-20-2 391962-21-3 391962-22-4,
 Carboxylesterase (human) 391962-24-6, Oxygenase, steroid 21-mono-
 (human) 391962-25-7, Protein (human gene CYP11A) 391962-26-8, Protein
 (human gene CYP2D) 391962-27-9 391962-28-0 391962-29-1
 391962-30-4, Serum paraoxonase (human gene PON) 391962-31-5
 391962-32-6, Monoamine oxidase A (human gene MAOA) 391962-35-9,
 Monoamine oxidase B (human gene MAOB) 391962-36-0, TB3-1 (human)

391962-37-1 391962-38-2 391962-39-3, UDP-glucuronosyltransfer ase
(human) 391962-40-6 391962-41-7, HsLim15 (human gene HsLIM15)
391962-42-8, Dehydrogenase, acyl coenzyme A (human) 391962-43-9, Protein
(human 290-amino acid) 391962-44-0 391962-48-4, Protein (human
503-amino acid) 391962-49-5, Cytochrome P450 (human gene CYP4A11)
391962-50-8, Hydrolase, bleomycin (human clone 1-1) 391962-51-9,
NADH-cytochrome-b5 reductase (human) 391962-52-0 391962-53-1
391962-54-2, GammaC-crystallin (human gene CRYGC) 391962-55-3, Protein
(human gene CRYG2) 391962-56-4 391962-57-5, Protein (human 511-amino
acid) 391962-58-6, Protein (human gene SOD3) 391962-59-7 391962-60-0
391962-61-1 391962-62-2, Protein (human 270-amino acid) 391962-63-3,
Mu-crystallin (human) 391962-64-4 391962-65-5 391962-66-6, Calnexin
(human) 391962-67-7, Calnexin (human) 391962-68-8 391962-69-9,
Cyclophilin-40 (human) 391962-70-2 391962-71-3, Zeta-crystallin
(human) 391962-72-4 391962-73-5 391962-74-6, Protein (human gene
p23) 391962-75-7, Endonuclease (human) 391962-76-8 391962-77-9,
Protein (human gene PPOL) 391962-78-0, Protein (human gene RAG1)
391962-79-1, Protein (human 108-amino acid) 391962-80-4, Protein (human
gene LIG1) 391962-81-5 391962-82-6, Protein (human gene XPAC)
391962-88-2 391962-89-3 391962-90-6 391962-91-7, Calreticulin (human
RAJI cell gene CALR) 391962-92-8 391962-93-9, α B-Crystallin
(human) 391962-94-0, Protein (human 95-amino acid) 391962-95-1,
AlphaA-crystallin (human gene CRYA1) 391962-96-2 391962-97-3
391962-98-4 391962-99-5 391963-00-1 391963-01-2, PLC alfa (human)
391963-04-5, P58 (human) 391963-05-6 391963-06-7 391963-07-8, Aryl
sulfotransferase (human) 391963-08-9, Dihydropyrimidine dehydrogenase
(human) 391963-09-0, Helicase II (human gene RAD54L) 391963-10-3
391963-12-5, CSA protein (human clone pCSA5 gene CSA) 391963-13-6
391963-14-7 391963-15-8 391963-16-9, XRCC4 (human) 391963-17-0
391963-18-1 391963-19-2 391963-22-7 391963-23-8, Protein (human
527-amino acid) 391963-24-9, Protein (human 361-amino acid)
391963-28-3 391963-29-4 391963-30-7 391963-31-8 391963-32-9
391963-33-0, Protein (human 304-amino acid) 391963-34-1, Protein (human
377-amino acid) 391963-35-2 391963-36-3 391963-37-4, Protein (human
556-amino acid) 391963-38-5 391963-39-6, Protein (human cell line C32
gene HAP1) 391963-40-9, AP endonuclease 1 (human gene HAP1)
391963-41-0, Heme oxygenase-2 (human) 391963-42-1 391963-43-2,
Colligin (human) 391963-44-3, Collagen binding protein 2 (human)
391963-45-4 391963-46-5 391963-47-6, Protein (human gene RAD54)
391963-48-7 391963-49-8, Protein (human gene XRCC2) 391963-50-1
391963-51-2, Protein (human 515-amino acid) 391963-52-3 391963-53-4
391963-54-5 391963-55-6, Protein (human 1279-amino acid) 391963-56-7
391963-57-8, Protein (human 152-amino acid) 391963-58-9, Immunophilin
(human) 391963-63-6, Protein (human gene IL7R) 391963-64-7, Protein
(human 439-amino acid) 391963-65-8, Interleukin 2 receptor (human)
391963-66-9, Protein (human gene IGF2) 391963-67-0 391963-68-1
391963-69-2, Protein (human 391-amino acid) 391963-70-5, Protein (human
gene MYB) 391963-71-6 391963-72-7 391963-73-8 391963-74-9
391963-75-0 391963-76-1 391963-77-2, Protein (human gene IFNGR1)
391963-78-3 391963-79-4, Adenosine receptor A3 (human) 391963-80-7,
Thrombin receptor (human) 391963-81-8 391963-82-9, GATA-binding
protein (human gene GATA-2) 391963-83-0 391963-84-1 391963-85-2,
Protein (human 448-amino acid) 391963-86-3 391963-87-4 391963-88-5
391963-89-6, DNA-binding protein (human gene SMBP2) 391963-90-9,
Transcription activator (human) 391963-91-0, DNA-binding protein (human)
391963-92-1, CACCC box-binding protein (human) 391963-93-2 391963-94-3
391963-95-4, Prostaglandin E2 receptor (human) 391963-96-5
391963-97-6, AES-1 (human) 391963-98-7 391963-99-8, SRE-binding
protein (human gene CNBP) 391964-00-4, Protein (human 423-amino acid)
391964-01-5, COUP-TF (human) 391964-03-7, DNA-binding protein (human
gene APRF) 391964-04-8, HSNF2b (human) 391964-05-9 391964-06-0, DP2
(human clone 3kd11 gene Humdp2) 391964-07-1, Glia maturation factor
 β (human) 391964-08-2 391964-09-3 391964-10-6, Protein (human
gene JUN) 391964-12-8, Protein (human gene CSF1) 391964-13-9

391964-14-0 391964-15-1 391964-16-2, Protein (human gene LAG2)
 391964-17-3, Neuroleukin (human) 391964-18-4 391964-19-5, Interleukin
 13 (human) 391964-20-8, Thrombopoietin (human) 391964-21-9, Protein
 (human 640-amino acid) 391964-22-0 391964-23-1 391964-24-2, Protein
 (human gene BMP1) 391964-25-3, Protein (human gene BMP2) 391964-26-4,
 Protein (human 92-amino acid) 391964-27-5 391964-28-6, Protein (human
 gene IGFBP1) 391964-29-7 391964-30-0, Protein (human gene IGFBP1)
 391964-31-1, Protein (human gene RNN) 391964-32-2 391964-33-3
 391964-34-4, Pleiotrophin (human) 391964-35-5, Interleukin 11 (human
 gene IL11) 391964-36-6, Stem cell factor (human gene SCF) 391964-37-7
 391964-38-8 391964-39-9, Connective tissue growth factor (human)
 391964-40-2, Protein (human gene RYK) 391964-41-3 391964-42-4
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; human stress genes identified using DNA
 microarrays)

IT 391964-43-5 391964-44-6, Protein (human 93-amino acid) 391964-45-7
 391964-46-8 391964-47-9, Placenta growth factor (PlGF) (human)
 391964-48-0, CDw40 (human cell line Raji) 391964-49-1 391964-50-4,
 Protein (human 527-amino acid) 391964-51-5 391964-52-6, E4TF1-47
 (human strain HeLa S3) 391964-53-7, Alpha1(E)-catenin (human)
 391964-54-8 391964-55-9, Protein (human 180-amino acid) 391964-56-0,
 Protein (human gene MXI1) 391964-57-1 391964-58-2, Focal adhesion
 kinase (human gene FAK) 391964-59-3 391964-60-6, Receptor TR3 (human)
 391964-61-7, RORalpha1 (human clone lambda hR5) 391964-62-8
 391964-63-9 391964-64-0 391964-65-1 391964-66-2 391964-67-3
 391964-68-4, Nuclear factor I-X (human) 391964-69-5, Protein kinase
 (human gene MLK-3) 391964-70-8 391964-71-9 391964-72-0, Protein
 (human gene GNAZ) 391964-73-1, Protein (human 153-amino acid)
 391964-74-2, Protein (human 217-amino acid) 391964-75-3 391964-76-4,
 Protein (human 467-amino acid) 391964-77-5, Protein (human 431-amino
 acid) 391964-78-6, Protein (human gene PTMA) 391964-79-7, GTP-binding
 protein (human gene RAB2) 391964-80-0, Protein (human 214-amino acid)
 391964-81-1, Protein (human gene TCF3) 391964-82-2 391964-83-3
 391964-84-4 391964-85-5 391964-86-6, Protein (human HL-60 cell gene
 ETR101) 391964-87-7, Protein (human 432-amino acid) 391964-88-8
 391964-89-9 391964-90-2 391964-91-3 391964-92-4 391964-93-5
 391964-94-6 391964-95-7, Protein (human cell line HEL gene FLI-1)
 391964-96-8, FLI-1 (human cell line HEL gene FLI-1) 391964-97-9
 391964-98-0, Protein (human gene SATB1) 391965-00-7 391965-01-8
 391965-02-9 391965-03-0 391965-05-2 391965-06-3 391965-07-4,
 Transcription factor LCR-F1 (human) 391965-08-5 391965-09-6
 391965-10-9 391965-11-0 391965-12-1, Protein ICH-1L (human gene Ich-1)
 391965-13-2 391965-14-3, Protein (human clone hdlkaag gene dlk)
 391965-15-4, Protein (human 728-amino acid) 391965-16-5 391965-17-6,
 P120 antigen (human) 391965-18-7, ZFX product, isoform 1 (human gene
 ZFX) 391965-19-8 391965-20-1 391965-21-2, Glutamate receptor (human
 gene GLUR5) 391965-22-3, Protein (human gene INHA) 391965-23-4
 391965-24-5 391965-25-6 391965-26-7, Protein (human gene cdc25A)
 391965-28-9, Protein (human 648-amino acid) 391965-29-0 391965-30-3,
 Protein (human gene ABL1) 391965-31-4, Cyclin (human) 391965-32-5,
 Protein (human 155-amino acid) 391965-33-6 391965-34-7, Gst-pi protein
 (human) 391965-35-8, Protein (human 222-amino acid) 391965-36-9,
 D-type cyclin (human gene CCND2) 391965-37-0, GTP-binding protein (human
 gene rhoA) 391965-38-1, Glutathione peroxidase (human) 391965-39-2,
 Protein (human clone bcl-xS gene bcl-xS) 391965-40-5 391965-41-6,
 Cyclin H (human clone F11-1) 391965-42-7 391965-43-8, Protein (human
 gene ITGB5) 391965-44-9 391965-45-0, Protein (human gene LYAM1)
 391965-46-1, Protein (human 798-amino acid) 391965-48-3 391965-49-4,
 Protein (human gene SP1) 391965-50-7 391965-51-8 391965-52-9, MAP
 kinase kinase 3 (human gene MKK3) 391965-53-0, MAP kinase kinase 4
 (human gene MKK4) 391965-54-1, Protein (human 394-amino acid)
 391965-55-2, Protein (human clone RB-[1,5] gene RB1) 391965-56-3,
 Protein (human 543-amino acid) 391965-57-4 391965-58-5 391965-59-6

391965-60-9, Protein (human gene APC) 391965-61-0, Sp2 protein (human cell line Molt13) 391965-62-1, Sp3 protein (human cell line Hut78)
 391965-63-2, P19INK4d (human) 391965-64-3, Cyclin G1 (human)
 391965-66-5 391965-67-6, Protein (human 326-amino acid) 391965-69-8, JunD protein (human gene junD) 391965-70-1, C-src-kinase (human clone 12a1) 391965-71-2, Vimentin (human clone vim6) 391965-72-3, FAST kinase (human gene fast) 391965-73-4, Beta-catenin (human cell line 5637) 391965-74-5, Protein (human HeLa cell gene MAT1) 391965-75-6, Tyrosine phosphatase (human) 391965-76-7 391965-77-8 391965-78-9
 391965-79-0, Protein Bcl-2 (human gene BAK) 391965-80-3 391965-81-4
 391965-83-6, Inhibitor of apoptosis protein 2 (human) 391965-84-7
 391965-85-8 391965-87-0 391965-88-1, FAN protein (human)
 391965-89-2, Serotonin 5-HT3 receptor (human) 391965-90-5, Protein (human gene clk2) 391965-91-6, Protein (human gene clk3) 391965-92-7, Protein (human gene clk1) 391965-93-8, Protein (human gene IGFBP1)
 391965-95-0 391965-96-1 391965-97-2 391965-98-3 391965-99-4
 391966-00-0, Transcription factor TAFII31 (human) 391966-02-2, RACH1 (human gene RACH1) 391966-03-3, C-1 (human gene C-1) 391966-04-4
 391966-05-5 391966-06-6, Bcl-w (human gene bcl-w) 391966-08-8
 391966-09-9 391966-10-2 391966-11-3 391966-12-4 391966-13-5
 391966-14-6, Troponin I (human) 391966-15-7, Protein (human gene ARL1)
 391966-17-9, Angiogenin (human gene ANG) 391966-18-0, Protein (human 572-amino acid) 391966-19-1, Protein (human 218-amino acid)
 391966-20-4, Protein (human 514-amino acid) 391966-21-5, Protein (human 603-amino acid) 391966-24-8 391966-25-9, Protein (human 128-amino acid) 391966-27-1 391966-29-3, Protein (human gene MPP1) 391966-30-6
 391966-31-7 391966-32-8, Heat shock protein hsp40-3 (human)
 391966-33-9 391966-34-0, Alpha-actinin (human gene ACTN3) 391966-35-1
 391966-36-2 391966-37-3, Tob family (human clone tob4) 391966-38-4, Lamin B2 (human gene LAMB2) 391966-39-5, Protein (human gene ASGR1)
 391966-40-8 391966-41-9, Histone-binding protein (human) 391966-42-0, POM-ZP3 (human) 391966-43-1, HZW10 (human cell line HeLa gene HZW10)
 391966-44-2, K-Cl cotransporter (human gene hKCC1) 391966-45-3
 391966-46-4 391966-47-5 391966-48-6 391966-49-7, Kinesin-2 (human gene HK2) 391966-53-3, DnaJ protein (human gene HSPF2) 391966-56-6
 391966-58-8, KE05 protein (human) 391966-60-2 391966-61-3
 391966-62-4, Homer-3 (human clone 376124) 391966-63-5, Ceramidase, glucosyl- (human HL-60 cell) 391966-64-6 391966-65-7, Intestinal trefoil factor (human) 391966-66-8 391966-67-9,
 Copper monamine oxidase (human) 391966-68-0 391966-69-1, Ki nuclear autoantigen (human) 391966-70-4, Centromere protein-A (human gene CENP-A) 391966-72-6, SMCY (human gene H-Y) 391966-74-8 391966-75-9, DGCR6 (human cell line HeLa) 391966-76-0, Nucleosome assembly protein 2 (human) 391966-77-1 391966-78-2, Alpha-centractin (human clone FC1519) 391966-79-3, Nucleoporin-like protein (human) 391966-80-6
 391966-81-7 391966-82-8, Protein (human 275-amino acid) 391966-83-9
 391966-84-0, Carbonic anhydrase IV (human) 391966-85-1, RNA-binding protein (human clone E5.1) 391966-86-2 391966-87-3, Protein (human 225-amino acid) 391966-88-4, Protein (human gene AHSG) 391966-89-5, Fibrillarin (human gene FBL) 391966-90-8 391966-91-9 391966-93-1, Phosphoprotein CtBP (human) 391966-94-2 391966-96-4 391966-97-5
 391966-98-6 391966-99-7 391967-00-3 391967-01-4 391967-02-5
 391967-03-6 391967-04-7 391967-05-8, Protein (human 255-amino acid)
 391967-07-0, Protein (human 412-amino acid)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (amino acid sequence; human stress genes identified using DNA microarrays)

IT 391975-35-2, Protein (human 802-amino acid) 391975-36-3 391975-37-4, Connexin 40 (human) 391975-38-5, Involucrin (human gene IVL)
 391975-39-6 391975-40-9, Protein (human 283-amino acid) 391975-41-0
 391975-44-3 391975-47-6 391975-48-7 391975-50-1 391975-51-2, Alanine aminotransferase (human) 391975-52-3, VEGF-D (human)
 391975-53-4, Protein (human gene ANT1) 391975-54-5, Protein (human gene

DRA) 391975-57-8, Protein (human 430-amino acid) 391975-58-9
391975-59-0 391975-60-3 391975-62-5, Uncoupling protein (human gene
UCP) 391975-63-6 391975-64-7 391975-66-9, Prostaglandin
transporter hPGT (human) 391975-67-0 391975-68-1, Protein (human
515-amino acid) 391975-69-2 391975-71-6 391975-72-7 391975-73-8
391975-74-9, Organic cation transporter (human) 391975-77-2, SMP-30
(human clone pHSMMP6) 391975-79-4 391975-80-7, P58/GTA protein kinase
(human) 391975-81-8 391975-82-9 391975-83-0, Protein (human gene
LMP2) 391975-84-1, ABC-transporter (human gene TAP1) 391975-85-2,
Protein (human gene LMP7) 391975-86-3, Protein (human gene TAP2)
391975-87-4, Class II beta chain (human gene DOB) 391975-88-5
391975-89-6 392341-43-4, Paraoxonase-3 (human gene PON3) 392341-44-5
392341-45-6 392341-47-8, Selenoprotein P (human) 392341-48-9, Protein
(human gene COL11A1) 392341-49-0 392341-50-3, Pro-a2(XI) (human gene
COL11A2) 392341-51-4, Pro-a2(XI) (human gene COL11A2) 392341-52-5,
Pro-a2(XI) (human gene COL11A2) 392341-55-8, Protein (human gene COL1A1)
392341-56-9 392341-58-1, Protein (human 327-amino acid) 392341-59-2
392341-60-5, Glutathione peroxidase (human) 393588-68-6 393588-69-7
393588-70-0 393588-71-1 393588-72-2 393593-31-2, Protein (human
236-amino acid)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(amino acid sequence; human stress genes identified using DNA
microarrays)

AB Human stress gene arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The average length of the polynucleotide probes is 50-1000 nucleotides. The d. of the spots on the array did not exceed 400/cm² and the spots had a diameter ranging between 10 and 5000 μm. Furthermore, the number of polynucleotide probe spots on the array ranged between 50 and 2000 nucleotides. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes. Two hundred thirty-six different human stress genes were identified using this approach.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 17629PCTAP	FOR FURTHER ACTION		See item 4 below
International application No. PCT/US2004/027777	International filing date (<i>day/month/year</i>) 25 August 2004 (25.08.2004)	Priority date (<i>day/month/year</i>) 03 October 2003 (03.10.2003)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant ALLERGAN, INC.			

1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).

2. This REPORT consists of a total of 8 sheets, including this cover sheet.

In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.

3. This report contains indications relating to the following items:

<input checked="" type="checkbox"/> Box No. I	Basis of the report
<input checked="" type="checkbox"/> Box No. II	Priority
<input checked="" type="checkbox"/> Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/> Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/> Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input type="checkbox"/> Box No. VI	Certain documents cited
<input type="checkbox"/> Box No. VII	Certain defects in the international application
<input type="checkbox"/> Box No. VIII	Certain observations on the international application

4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).

		Date of issuance of this report 03 April 2006 (03.04.2006)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Agnes Wittmann-Regis	
Facsimile No. +41 22 740 14 35	Telephone No. +41 22 338 89 70	

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

REC'D 02 DEC 2004

WIPO PCT

PCT

To:

see form PCT/ISA/220

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

Date of mailing
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference
see form PCT/ISA/220

FOR FURTHER ACTION

See paragraph 2 below

International application No.
PCT/US2004/027777

International filing date (day/month/year)
25.08.2004

Priority date (day/month/year)
03.10.2003

International Patent Classification (IPC) or both national classification and IPC
A61K38/17, A61K31/5575, A61P27/02

Applicant
ALLERGAN, INC

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or Industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for International preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer

Tardi, C

Telephone No. +49 89 2399-8180



**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/US2004/027777

Box No. I Basis of the opinion

1. With regard to the **language**, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material:
 a sequence listing
 table(s) related to the sequence listing
 - b. format of material:
 in written format
 in computer readable form
 - c. time of filing/furnishing:
 contained in the international application as filed.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority for the purposes of search.
3. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/US2004/027777

Box No. II Priority

1. The following document has not been furnished:

copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).
 translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).

Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.

2. This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/US2004/027777

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

the entire international application,
 claims Nos. 14-21

because:

the said international application, or the said claims Nos. 14-21 regarding industrial applicability relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
 the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
 no international search report has been established for the whole application or for said claims Nos.
 the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form has not been furnished
 does not comply with the standard
the computer readable form has not been furnished
 does not comply with the standard

the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
 See separate sheet for further details

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/US2004/027777

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or
industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-28
	No: Claims	
Inventive step (IS)	Yes: Claims	1-28
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-13,22-28
	No: Claims	

2. Citations and explanations

see separate sheet

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/US2004/027777

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

- 1) Claims 14-21 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 1) Reference is made to the following documents:
D1: EP-A-0 435 682 (ALLERGAN INC) 3 July 1991 (1991-07-03)
D2: US 2003/186886 A1 (PODOLSKY DANIEL K) 2 October 2003 (2003-10-02)
Unless indicated otherwise, the relevant passages are those mentioned in the search report.
- 2) Novelty and inventive step (Art. 33(2) and 33(3) PCT)
It is already known from D1 that the clinical potentials of prostaglandins in the management of conditions associated with increased ocular pressure, e.g. glaucoma are greatly limited by side effects such as ocular surface (conjunctival) hyperaemia and foreign-body sensation.

Document D2 discloses that trefoil peptides are useful for the treatment of eye disorders, such as ocular inflammation, or disorders caused by topical drugs. However D2 contains no hint that trefoil peptides might be useful for alleviating hyperaemia associated with the topical use of prostaglandins in the treatment of glaucoma.

Therefore the subject-matter of the present application appears to be new and inventive.

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/US2004/027777

3) For the assessment of the present claims 14-21 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.